Viking Therapeutics had its Relative Strength (RS) Rating upgraded from 73 to 82 Thursday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
History shows that the best stocks tend to have an RS Rating north of 80 as they launch their biggest climbs.
Viking Therapeutics has moved more than 5% past a 3.50 entry in a first-stage double bottom, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% earnings growth last quarter, while sales growth came in at 0%.
Viking Therapeutics earns the No. 285 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
